Compare Biogen Inc (BIIB) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares MSCI United Kingdom (FTSE) — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while iShares MSCI United Kingdom (FTSE) trades at $48.32. Which is the better fit depends on your goals.
| BIIB | EWU | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $48.68 |
52-Week Low | $128.93 | $40.90 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
EWU, the iShares MSCI United Kingdom ETF, trades at $48.37, down 0.25% on the day, with a bullish technical outlook supported by moving averages and strong trend indicators like ADX. Recent institutional activity includes Balefire LLC acquiring shares and Bank of America reducing its stake. The ETF is influenced by FTSE 100 performance, oil price volatility, and UK political developments under new Prime Minister Andy Burnham.
The outlook for EWU is cautiously optimistic, driven by bullish technical signals and exposure to UK equities, but risks from Middle East tensions, oil price swings, and political uncertainty may curb gains. Investors should weigh the ETF's diversification benefits against macroeconomic headwinds affecting British markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
